FIELD: biotechnology.
SUBSTANCE: group of inventions including a bispecific antibody and a method for its production is described. The bispecific antibody comprises a first antigen-binding fragment that specifically binds to an epitope in the RBD receptor-binding domain of SARS-COV2 SARS-COV2 spike protein S and a second antigen-binding fragment that specifically binds to human CD3, the said antibody comprising the amino acid sequence of SEQ ID NO: 1.
EFFECT: invention expands the arsenal of agents that specifically bind to an epitope in the RBD receptor-binding domain of the SARS-COV2 SARS-COV2 spike protein S and specifically bind to human CD3.
8 cl, 7 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| POLYPEPTIDE MODULE FOR BINDING CONSERVATIVE EPITOPE OF RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 CORONAVIRUS | 2022 |
|
RU2809183C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| 5-[4-(1,3-BENZOTHIAZOL-2-YL)PHENYL]-10,15,20-TRIS(1-METHYLPYRIDINIUM-3-YL)PORPHYRIN TRIIOODIDE, SHOWING THE BINDING PROPERTY OF THE SARS-CoV-2 VIRUS SPIKE PROTEIN | 2021 |
|
RU2773397C1 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| POLYPEPTIDE WITH ANTI-SARS-COV-2 ACTIVITY AND PROLONGED CIRCULATION TIME IN BLOOD FLOW | 2023 |
|
RU2822355C1 |
